Gene expression of estrogen receptor-alpha in orbital fibroblasts in Graves’ ophthalmopathy


Autoria(s): Cury, Sarah Santiloni; Oliveira, Miriane; Síbio, Maria Teresa; Clara, Sueli; Luvizotto, Renata De Azevedo Melo; Conde, Sandro; Jorge, Edson Nacib; Nunes, Vania Dos Santos; Nogueira, Célia Regina; Mazeto, Gláucia Maria Ferreira Da Silva
Contribuinte(s)

Universidade Estadual Paulista (UNESP)

Data(s)

26/08/2015

26/08/2015

01/06/2015

Resumo

Graves’ ophthalmopathy (GO) is one of the most severe clinical manifestations of Graves’ disease (GD), and its treatment might involve high-dose glucocorticoid therapy. The higher incidence of GO among females, and the reported association between polymorphisms of estrogen receptor (ER) and GD susceptibility have led us to question the role of estrogen and its receptor in GO pathogenesis. We, thus, assessed estrogen receptor-alpha (ERA) gene expression in cultures of orbital fibroblasts from a patient with GO before (controls) and after treatment with 10 nM and 100 nM dexamethasone (DEX). Orbital fibroblasts showed ERA gene expression. In the cells treated with 10 nM and 100 nM DEX, ERA gene expression was, respectively, 85% higher and 74% lower, than in the control group. We concluded that ERA gene expression is found in the orbital fibroblasts of patient with GO, which may be affected by glucocorticoids in a dose-related manner. Arch Endocrinol Metab. 2015;59(3):273-6

Formato

273-276

Identificador

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S2359-39972015000300273&lng=en&nrm=iso&tlng=en

Archives of Endocrinology and Metabolism, v. 59, n. 3, p. 273-276, 2015.

2359-3997

http://hdl.handle.net/11449/127295

http://dx.doi.org/10.1590/2359-3997000000050

S2359-39972015000300273

S2359-39972015000300273.pdf

Idioma(s)

eng

Publicador

Sociedade Brasileira de Endocrinologia e Metabologia

Relação

Archives of Endocrinology and Metabolism

Direitos

openAccess

Tipo

info:eu-repo/semantics/article